Korsana Biosciences (KRSA) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$3.19

Estimate

-$0.67

Surprise

-372.8%

Score today

5.0/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Korsana Biosciences (KRSA) reported a wider loss than forecast — adjusted EPS of -$3.19 against the -$0.67 estimate (a 372.8% shortfall).

• Korsana Biosciences Reports Third Quarter 2026 Financial Results and Corporate Update — fiscal.ai, 2026-11-05
• Korsana Biosciences Q3 EPS $(3.19) Misses $(0.85) Estimate — benzinga, 2026-11-05

TrendMatrix currently rates KRSA Sell at 5.0/10; no pre/post engine snapshot brackets this report.

2 of the last 3 quarters beat the estimate; this quarter's -372.8% surprise compares with a -97.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$31.05

Price target

$38.28

Stop

$28.88

Upside to target

+23.3%

Reward-to-risk

1.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-08 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.41B

P/E (fwd)

-8.7

52-week range

$7.19–$59.36

Off 52-week high

47.7%

RSI (14)

48

Volume vs avg

0.41×

Score today

5.0/10